Marina Biotech Regains Compliance With Exchange Act Reporting Obligations
August 20, 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - Aug 20, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced...
Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic Malignancy Cohort of On-Going Trial
June 12, 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - Jun 12, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced...
Marina Biotech Receives Decision to Grant Japanese Patent for Its SMARTICLES Nucleic Acid Delivery Technology
June 05, 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - Jun 5, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that...
Marina Biotech to Present at the LD Micro Invitational 2014
May 28, 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - May 28, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that...
Marina Biotech Provides Organizational Update
May 14, 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - May 14, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today provided an...
Marina Biotech Presents Clinical Data Demonstrating Delivery of Both Single and Double-Stranded Nucleic Acids to Tumors
May 06, 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - May 6, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, presented data from...
Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-Based Diagnostics and Therapeutics for Rare Diseases
April 02, 2014 09:08 ET
|
Marina Biotech, Inc.
PRINCETON, NJ and REHOVOT, ISRAEL and BOSTON, MA--(Marketwired - Apr 2, 2014) - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and...
Marina Biotech to Use Its RNAi, Antisense and microRNA Therapeutics Platform to Develop Drugs for Rare Diseases
March 11, 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - Mar 11, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today...
Marina Biotech Continues to Build Worldwide Patent Protection for Its SMARTICLES(R) Nucleic Acid Delivery Technology
February 27, 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - Feb 27, 2014) - Marina Biotech, Inc. (OTC Pink: MRNA), a leading oligonucleotide-based drug discovery and development company focused on rare diseases, announced...
Marina Biotech Announces $6 MM Convertible Preferred Stock Financing and Conversion to Common Stock of the Company's Promissory Note
February 24, 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - Feb 24, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company focused on rare diseases, announced today...